ISSN: 0970-938X (Print) | 0976-1683 (Electronic)

Biomedical Research

An International Journal of Medical Sciences

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

XRCC1 rs1799782 polymorphism and objective response rate in NSCLC patients treated with platinum-based chemotherapy

Background: Some previous studies suggested that XRCC1 rs1799782 polymorphism was associated with the objective response rate (ORR) of platinum-based chemotherapy. However, the results were not coincident. Thus, we conducted this meta-analysis.

Methods: The databases of PubMed, Embase, Cochrane Library, and Web of Science were searched. This meta-analysis was performed using Stata version 12.0 (StataCorp LP, TX, USA).

Results: In this meta-analysis study, a total of 13 relevant articles with 2540 NSCLC patients were enrolled. Results of this meta-analysis study showed that the NSCLC patients with XRCC1 rs1799782 Trp/Trp genotype were associated with worse ORR (OR=1.37; 95%CI, 1.01-1.79). In addition, XRCC1 rs1799782 Arg/Trp genotype was associated with worse ORR (OR=1.41; 95%CI, 1.14-1.75). Furthermore, NSCLC patients with XRCC1 rs1799782 Trp/Trp or Arg/Trp genotype also showed worse ORR (OR=1.39; 95%CI, 1.02-1.76).

Conclusions: In conclusion, this meta-analysis suggested that XRCC1 rs1799782 polymorphism was significantly associated with ORR in NSCLC patients treated with platinum-based chemotherapy.


Author(s): Peng-Cheng Wang, Xing Du, Yi Wang, Xiao-Li Zheng

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+